NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

RGNX

Regenxbio Inc

Jul 03 • 04:00PM ET

8.74

Dollar change +0.12
Percentage change 1.39	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP BMRN NTLA EDIT QURE SRPT ADVM BLUE VYGR CLLS

| Held by: VTI IWM XBI VXF IWN IBB VTWO SCHA DFAT FESM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.14	Insider Own	9.39%	Shs Outstand	50.12M	Perf Week	-0.11%
Market Cap	440.40M	Forward P/E	-	EPS next Y	-1.51	Insider Trans	-0.43%	Shs Float	45.66M	Perf Month	-13.72%
Enterprise Value	306.06M	PEG	-	EPS next Q	-0.94	Inst Own	86.64%	Short Float	12.07%	Perf Quarter	23.97%
Income	-157.69M	P/S	2.81	EPS this Y	93.72%	Inst Trans	2.33%	Short Ratio	4.78	Perf Half Y	20.89%
Sales	156.72M	P/B	1.60	EPS next Y	-422.91%	ROA	-28.16%	Short Interest	5.51M	Perf YTD	13.07%
Book/sh	5.47	P/C	1.64	EPS next 5Y	23.05%	ROE	-47.44%	52W High	15.36 -43.10%	Perf Year	-21.05%
Cash/sh	5.32	P/FCF	-	EPS past 3/5Y	- -12.18%	ROIC	-44.14%	52W Low	5.03 73.58%	Perf 3Y	-64.15%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-43.84% 18.79%	Gross Margin	68.92%	Volatility	7.52% 8.71%	Perf 5Y	-77.05%
Dividend TTM	-	EV/Sales	1.95	EPS Y/Y TTM	46.66%	Oper. Margin	-100.41%	ATR (14)	0.73	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.93	Sales Y/Y TTM	80.70%	Profit Margin	-100.62%	RSI (14)	49.53	Recom	1.38
Dividend Gr. 3/5Y	- -	Current Ratio	2.93	EPS Q/Q	108.54%	SMA20	-1.63%	Beta	1.10	Target Price	33.15
Payout	-	Debt/Eq	0.49	Sales Q/Q	469.79%	SMA50	-2.87%	Rel Volume	0.37	Prev Close	8.62
Employees	353	LT Debt/Eq	0.30	Earnings	May 12 AMC	SMA200	1.63%	Avg Volume	1.15M	Price	8.74
IPO	Sep 17, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-73.93% -17.49%	Trades		Volume	423,944	Change	1.39%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-11-25	Downgrade	Goldman	Buy → Neutral	$38 → $14
Feb-07-25	Resumed	Raymond James	Outperform	$27
Nov-15-24	Resumed	Morgan Stanley	Overweight	$22
Oct-10-24	Resumed	Raymond James	Outperform	$18
Jun-07-24	Initiated	Goldman	Buy	$38
Mar-11-24	Initiated	H.C. Wainwright	Buy	$36
Mar-08-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$20 → $35
Mar-06-24	Upgrade	Leerink Partners	Market Perform → Outperform	$37
Feb-21-24	Resumed	Raymond James	Outperform	$45
Nov-01-23	Initiated	Stifel	Buy	$35
Jun-02-23	Initiated	Robert W. Baird	Outperform	$42
Jun-23-22	Initiated	Berenberg	Buy	$61
Dec-15-21	Initiated	Wedbush	Neutral	$29
Oct-19-21	Resumed	Morgan Stanley	Overweight	$62 → $50
Jan-06-21	Upgrade	Raymond James	Outperform → Strong Buy	$60
Dec-16-20	Initiated	UBS	Buy	$57
Jun-25-20	Resumed	BofA/Merrill	Buy	$9
Jun-25-20	Resumed	BofA/Merrill	Buy	$60
May-13-20	Initiated	RBC Capital Mkts	Sector Perform	$42
Aug-20-19	Upgrade	SVB Leerink	Underperform → Mkt Perform	$38 → $37

Show Previous Ratings

Jun-20-25 11:27AM	Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street. (Barrons.com)
Jun-19-25 03:00AM	Gene Therapy Has Lost Support on Wall Street. There's Still Hope for Big Cures. (Barrons.com)
Jun-06-25 07:02AM	Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update (BioPharma Dive) +14.95%
Jun-05-25 07:05AM	REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE TRIAL OF RGX-202 (PR Newswire) -17.06%
Jun-02-25 07:05AM	REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE Trial of RGX-202 (PR Newswire) +16.95%
07:00AM	Loading…
May-20-25 07:00AM	Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff (BioPharma Dive)
May-19-25 04:05PM	REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million (PR Newswire) +10.12%
May-14-25 07:47AM	FDA to review Regenxbio's gene therapy BLA for Hunter syndrome (Pharmaceutical Business Review)
07:13AM	FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment (PR Newswire)
May-13-25 09:44AM	Q1 2025 Regenxbio Inc Earnings Call (Thomson Reuters StreetEvents)
07:05AM	REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II (PR Newswire)
03:09AM	Regenxbio Inc (RGNX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and Financial ... (GuruFocus.com)
May-12-25 05:25PM	Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates (Zacks) +5.98%
04:23PM	Regenxbio: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights (PR Newswire)
09:38AM	Loading…
May-09-25 09:38AM	What To Expect From Regenxbio Inc (RGNX) Q1 2025 Earnings (GuruFocus.com) +5.17%
May-08-25 07:05AM	REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting (PR Newswire)
May-06-25 07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire) -18.85%
May-05-25 10:00AM	Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks) -6.15%
May-04-25 08:00AM	Investing Groups Roundtable: Tariff Policy Impact - Part 3 (Seeking Alpha)
May-03-25 10:24PM	The 1-Minute Market Report May 4, 2025 (Seeking Alpha)
May-01-25 05:35PM	Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.80%
Apr-30-25 04:05PM	REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights (PR Newswire)
Apr-28-25 10:25AM	The 1-Minute Market Report April 27, 2025 (Seeking Alpha)
Apr-22-25 05:30AM	Trumps FDA Sends a Bullish Signal to Biotech (The Wall Street Journal) +17.24%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -5.45%
Mar-29-25 08:30AM	Undercovered Dozen: Delek Logistics, Perma-Fix, Consolidated Water, Rockwell Automation + (Seeking Alpha)
Mar-26-25 12:31PM	5 Reasons To Buy Regenxbio Right Now (SeekingAlpha)
Mar-23-25 07:18AM	Wall Street Week Ahead (SeekingAlpha)
Mar-20-25 07:53AM	Regenxbios DMD gene therapy drives 122.3% biomarker uptick in three-year-old (Clinical Trials Arena)
09:15AM	Loading…
Mar-19-25 09:15AM	REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE TRIAL OF RGX-202 GENE THERAPY (PR Newswire) +8.97%
Mar-14-25 09:39AM	Q4 2024 Regenxbio Inc Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Regenxbio Inc (RGNX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Resilience (GuruFocus.com)
Mar-13-25 05:25PM	Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:25PM	Regenxbio: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates (PR Newswire)
Mar-10-25 07:05AM	REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (PR Newswire) -5.21%
Mar-06-25 10:00AM	Will Regenxbio (RGNX) Report Negative Earnings Next Week? What You Should Know (Zacks)
04:09AM	Jim Cramer on REGENXBIO Inc. (RGNX): This Thing Just Does Nothing But Go Down (Insider Monkey)
Mar-04-25 07:31AM	REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases (PR Newswire)
Feb-26-25 04:05PM	REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights (PR Newswire)
Feb-25-25 04:05PM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-11-25 03:20PM	Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns (Benzinga) -7.10%
Feb-10-25 09:55AM	Wall Street Analysts Think Regenxbio (RGNX) Could Surge 333.01%: Read This Before Placing a Bet (Zacks)
Jan-30-25 07:05AM	REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025 (PR Newswire) +5.05%
Jan-24-25 09:55AM	Wall Street Analysts See a 357.36% Upside in Regenxbio (RGNX): Can the Stock Really Move This High? (Zacks)
03:00AM	Gene therapies have been uneven for DMD but these companies hope to turn the tide (Pharma Voice)
Jan-15-25 03:18PM	Regenxbio and Nippon Shinyaku forge $810m gene therapy deal (Pharmaceutical Technology) +5.53%
Jan-14-25 06:30AM	Regenxbio licenses gene therapies to Japans Nippon Shinyaku (BioPharma Dive)
05:00AM	REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases (PR Newswire)
Jan-13-25 08:31AM	AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program (PR Newswire) -7.46%
Jan-08-25 07:26AM	Regenxbio price target lowered to $22 from $25 at BofA (TipRanks)
Dec-06-24 06:29PM	Apollo Global Management and Workday Set to Join SandP 500; Others to Join SandP MidCap 400 and SandP SmallCap 600 (PR Newswire) +9.61% +6.16%
06:29PM	Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
Nov-19-24 12:32PM	Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy (Pharmaceutical Technology) -5.81%
Nov-18-24 07:05AM	REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA (PR Newswire) +5.40%
05:23AM	FDA endorses speedy approval path for Regenxbio Duchenne gene therapy (BioPharma Dive)
Nov-14-24 07:05AM	REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE Trial of RGX-202 (PR Newswire)
Nov-07-24 02:22AM	Regenxbio Inc (RGNX) Q3 2024 Earnings Call Highlights: Advancements in Gene Therapy and ... (GuruFocus.com) +18.66%
Nov-06-24 06:00PM	Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.72%
05:02PM	Regenxbio: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates (PR Newswire)
Nov-05-24 07:59AM	Regenxbio Inc (RGNX) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-04-24 07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Oct-30-24 07:05AM	REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights (PR Newswire)
Oct-21-24 07:05AM	REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024 (PR Newswire) -6.58%
Oct-18-24 07:05AM	REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting (PR Newswire)
Oct-17-24 03:04PM	JPMorgan Chase & Co. Reduces Stake in Regenxbio Inc (GuruFocus.com)
Sep-23-24 04:05PM	REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference (PR Newswire)
Sep-17-24 07:05AM	REGENXBIO Appoints Mitchell Chan as Chief Financial Officer (PR Newswire)
Sep-04-24 09:15AM	New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth (GlobeNewswire)
Sep-03-24 01:33PM	RegenxBio touts positive data for rare disease drug RGX-121 (Pharmaceutical Technology) -7.20%
08:04AM	REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect (PR Newswire)
Aug-29-24 04:05PM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-27-24 07:05AM	REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium (PR Newswire)
Aug-08-24 07:05AM	REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (PR Newswire)
06:00AM	7 Biotech Stocks to Buy for Their Game-Changing Potential (InvestorPlace)
Aug-06-24 09:55AM	Wall Street Analysts Think Regenxbio (RGNX) Could Surge 234.37%: Read This Before Placing a Bet (Zacks)
Aug-01-24 05:45PM	Regenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -6.60%
04:46PM	Regenxbio: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights (PR Newswire)
07:03AM	REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE TRIAL OF RGX-202 (PR Newswire)
Jul-30-24 07:01PM	Insider Sale: CEO Curran Simpson Sells Shares of Regenxbio Inc (RGNX) (GuruFocus.com)
Jul-28-24 09:09AM	Goldman Sachs Predicts up to 165% Surge for These 2 Strong Buy Stocks (TipRanks)
Jul-25-24 07:05AM	REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights (PR Newswire) +5.50%
Jul-12-24 09:59AM	Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains? (Zacks)
Jun-27-24 10:05AM	Why Did Analysts Maintain a Bullish Stance on REGENXBIO Inc. (RGNX) Despite Decline In Its Revenue Growth? (Insider Monkey)
Jun-26-24 04:36PM	Top 10 Small-Cap Stocks with Highest Upside Potential (Insider Monkey) -6.57%
Jun-25-24 04:32AM	Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock? (Zacks)
Jun-24-24 12:56PM	7 Biotech Stocks to Buy on the Dip: June 2024 (InvestorPlace) +6.41%
07:05AM	REGENXBIO Announces Expansion of AFFINITY DUCHENNE Trial to Include a New Cohort of Younger Patients (PR Newswire)
Jun-21-24 04:28PM	Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy (Investor's Business Daily)
06:40AM	Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy (Investor's Business Daily)
Jun-18-24 07:05AM	REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II (PR Newswire)
07:02AM	Sanofi taps Belharra for immune drug research; AstraZenecas new cancer drug falls short (BioPharma Dive)
Jun-12-24 08:00AM	Regenxbio CEO to step down after 15 years (BioPharma Dive)
07:05AM	REGENXBIO Announces Leadership Transition (PR Newswire)
Jun-05-24 07:05AM	REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (PR Newswire)
May-15-24 11:38AM	HC Wainwright Adjusts Price Target on REGENXBIO to $38 From $36, Maintains Buy Rating (MT Newswires)
May-10-24 02:30PM	Regenxbio Inc (RGNX) Q1 2024 Earnings: Misses Analyst Revenue and EPS Forecasts (GuruFocus.com)

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mills Kenneth T.	Director	May 12 '25	Option Exercise	3.76	20,602	77,464	495,705	May 14 04:49 PM
Mills Kenneth T.	Director	May 12 '25	Sale	7.91	20,602	163,046	475,103	May 14 04:49 PM
KENNETH MILLS	Director	May 12 '25	Proposed Sale	7.52	20,602	154,927		May 12 04:29 PM
Mills Kenneth T.	Director	Mar 27 '25	Option Exercise	3.76	30,752	115,628	475,103	Mar 31 05:05 PM
VITTAL VASISTA	Officer	Dec 30 '24	Proposed Sale	7.41	20,041	148,504		Dec 30 04:09 PM
KARABELAS ARGERIS N	Director	Oct 01 '24	Option Exercise	3.76	10,000	37,600	21,286	Oct 02 04:31 PM
KARABELAS ARGERIS N	Director	Oct 01 '24	Sale	10.11	10,000	101,052	11,286	Oct 02 04:31 PM
KARABELAS ARGERIS N	Director	Sep 03 '24	Option Exercise	3.76	10,000	37,600	21,286	Sep 04 08:20 PM
KARABELAS ARGERIS N	Director	Sep 03 '24	Sale	11.56	10,000	115,588	11,286	Sep 04 08:20 PM
Mills Kenneth T.	Director	Aug 08 '24	Option Exercise	0.85	36,316	30,869	444,351	Aug 12 04:58 PM
KARABELAS ARGERIS N	Director	Aug 01 '24	Option Exercise	3.85	10,100	38,874	21,386	Aug 05 06:39 PM
KARABELAS ARGERIS N	Director	Aug 01 '24	Sale	13.51	10,100	136,454	11,286	Aug 05 06:39 PM
Simpson Curran	Chief Executive Officer	Aug 01 '24	Sale	15.00	100	1,500	170,037	Aug 05 06:39 PM
ARGERIS N KARABELAS	Director	Aug 01 '24	Proposed Sale	14.25	31,000	441,750		Aug 01 04:34 PM
KARABELAS ARGERIS N	Director	Jul 29 '24	Option Exercise	12.74	11,000	140,140	22,286	Jul 30 05:01 PM
KARABELAS ARGERIS N	Director	Jul 29 '24	Sale	15.04	11,000	165,495	11,286	Jul 30 05:01 PM
Simpson Curran	Chief Executive Officer	Jul 29 '24	Sale	15.04	9,648	145,106	170,137	Jul 30 05:01 PM
CURRAN M SIMPSON	Director	Jul 29 '24	Proposed Sale	14.33	25,106	359,769		Jul 29 04:13 PM
Mills Kenneth T.	Director	Jul 25 '24	Option Exercise	3.76	15,369	57,787	423,404	Jul 26 05:00 PM
Mills Kenneth T.	Director	Jul 24 '24	Option Exercise	3.76	12,221	45,951	420,256	Jul 26 05:00 PM
Mills Kenneth T.	Director	Jul 25 '24	Sale	13.96	15,369	214,501	408,035	Jul 26 05:00 PM
Mills Kenneth T.	Director	Jul 24 '24	Sale	13.78	12,221	168,433	408,035	Jul 26 05:00 PM
Mills Kenneth T.	Director	Jul 17 '24	Option Exercise	3.76	2,210	8,310	410,245	Jul 18 05:05 PM
Mills Kenneth T.	Director	Jul 16 '24	Option Exercise	3.76	200	752	408,235	Jul 18 05:05 PM
Mills Kenneth T.	Director	Jul 17 '24	Sale	13.77	2,210	30,440	408,035	Jul 18 05:05 PM
Mills Kenneth T.	Director	Jul 16 '24	Sale	13.76	200	2,752	408,035	Jul 18 05:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RGNX

Regenxbio Inc

Upgrade your FINVIZ experience